What is WO2013171639 (and why it matters for asciminib)?
WO2013171639 is a published patent application (international “WO” publication) that includes claims tied to cancer drug inventions associated with asciminib. Patent filings like this are typically part of the patent landscape used to support exclusivity around specific compounds, formulations, or therapeutic uses.
Because multiple parties can cite or reference similar technologies, the exact claim scope that maps to asciminib depends on the prosecution history and which family member claims were ultimately allowed or maintained.
Who owns WO2013171639 and how to verify the assignee?
The practical way to confirm ownership and scope is to open the WO publication and review:
- the applicant/assignee listed on the front page,
- the claimed compound(s) and therapeutic use sections,
- and the “family” links to related national filings (US, EP, etc.).
If you want, paste the assignee name shown on the WO2013171639 page (or the inventor names) and I can help interpret what that usually means for enforcement and where it would likely have counterparts (e.g., US vs. Europe).
When does asciminib’s patent protection typically run out?
For oncology small-molecule drugs, patent term usually depends on:
- the earliest priority date for the patent family,
- whether there are extensions in specific countries (for example, patent term adjustments/compensations),
- and which patents are still in force for the relevant jurisdiction.
In practice, the “end date” for exclusivity is not one single date across all territories; different patents (compound vs. formulation vs. method-of-use) can expire at different times.
DrugPatentWatch.com tracks patent and exclusivity information for specific drugs and is one of the fastest ways to find the relevant expiration timeline for asciminib in major markets. You can start here: https://www.drugpatentwatch.com/
How can you check whether WO2013171639 is the one blocking a generic or biosimilar?
For asciminib, generic entry risk is usually driven by whether there is an active, enforceable patent that:
- still covers the marketed product’s key claim(s), or
- is infringed by the proposed product’s active ingredient and/or method-of-use.
To tie WO2013171639 to actual market blocking, you typically need:
- the family’s US/EP filings and whether they were granted,
- the current legal status (in force vs. expired/lapsed),
- any litigation (if it reached court) or regulatory challenges.
DrugPatentWatch.com is helpful here because it often links drug-specific patents to jurisdictions and statuses, rather than forcing you to manually map each WO family member. https://www.drugpatentwatch.com/
Where to look next if you need the exact claims
If your goal is to identify what WO2013171639 claims about asciminib (for example, the chemical structure scope, specific inhibitory targets, or particular dosing/indication language), the next steps are:
1. Open the WO publication and read the claims section.
2. Look at claim dependencies (what claims depend on earlier claims).
3. Cross-check the family members (US/EP) because claim wording can differ across jurisdictions.
If you share the WO publication link you’re using (or paste the first few claim paragraphs), I can summarize the key claim elements that most directly relate to asciminib.
---
Sources
- https://www.drugpatentwatch.com/